Inhibitory Antibodies

A monoclonal antibody is secreted by a single B lymphocyte clone which can only produce a kind of proprietary antibody against an antigen-determining cluster, and has the characteristics of single biological activity and particular specificity of binding with antigen.

The active sites of monoclonal antibody drugs involve a variety of tumor-related signaling pathways and targets. For example, the most common targets are epidermal growth factor receptor (EGFR), vascular endothelial growth factor (VEGF), and epidermal growth factor receptor -2 (her-2 /neu, or egfr-2). Besides, there is a group of targets that are getting a lot of attention called “immune checkpoints”.

After the activation of immune cells that regulate the anti-tumor immune response, a variety of highly expressed receptors on the surface of immune cells bind to the highly expressed ligands on the surface of tumor cells to reduce the strength of the immune response, thus down-regulating the intensity of tumor-related immune response. These immunoregulatory sites are known as immune checkpoints. Currently, the most widely studied immune checkpoints are PD-1, PD-L1, and CTLA-4.

Targetmol provides 30 monoclonal antibody drugs, including the above immune checkpoint inhibitors and other types of targeted antibody inhibitors, for scientific research only.

Cat. No.	Product name	CAS No.	Purity
T25593	Labetuzumab govitecan	1469876-18-3	98%
T25593	Labetuzumab govitecan is an anti-CEACAM5/SN-38 antibody-drug conjugate for therapy of refractory or relapsing metastatic colorectal cancer.
T36656	Anti-Spike-RBD Single Domain mAb		98%
T36656	Anti-Spike-RBD Single Domain mAb is a CHO cell derived Alpaca monoclonal VHH-huFc antibody, specifically binds to SARS-CoV-2 RBD with high affinity[1]. [1]. Chun...
T9927	Panitumumab	339177-26-3	98%
T9927	Panitumumab is a fully human IgG2 monoclonal antibody targeting the epidermal growth factor receptor EGFR).
T10497	Benralizumab	1044511-01-4	98%
T10497	Benralizumab (MEDI-563) is an IL-5Rα-directed cytolytic monoclonal antibody that induces rapid, direct and nearly complete depletion of eosinophils via enhanced ...
T35389	Sarilumab (anti-IL-6Rα)		98%
T35389
T9925	Ofatumumab	679818-59-8	98%
T9925	Ofatumumab is a fully human monoclonal antibody to CD20 which appears to inhibit early-stage B lymphocyte activation
T36647	Trastuzumab emtansine	1018448-65-1	98%
T36647	Trastuzumab emtansine (Ado-Trastuzumab emtansine) is an antibody-drug conjugate (ADC) that incorporates the HER2-targeted antitumor properties of trastuzumab wit...
T9914	Vedolizumab	943609-66-3	98%
T9914	Vedolizumab is a humanized monoclonal antibody that targets the α4β7 integrin for the treatment of Crohn's disease and ulcerative colitis.
T35397	Sacituzumab (anti-Trop-2)		98%
T35397
T35390	Magrolimab (anti-CD47)		98%
T35390
T39595	Disitamab vedotin	2136633-23-1	98%
T39595	Disitamab vedotin (RC48) is an antibody-drug conjugate (ADC) comprising a monoclonal antibody against human epidermal growth factor receptor 2 (HER2) conjugated ...
T35386	Elotuzumab (anti-SLAMF7)		98%
T35386
T36654	Anti-SARS-CoV-2 Spike mAb (CR3022)		98%
T36654	Anti-SARS-CoV-2 Spike mAb (CR3022) is a a CHO cell derived human monoclonal IgG1 antibody. It binds to both S1 domain of SARS-CoV/SARS-CoV-2 Spike protein[1][2...
T36651	Anti-MERS-2E6 mAb		98%
T36651	Anti-MERS-2E6 mAb (MERS-2E6; MERS Antibody-2E6), a human neutralizing antibody IgG1 (CHO expressed) that can compete for the binding of the virus Spike protein t...
T9922	Matuzumab	339186-68-4	98%
T9922	Matuzumab is a humanized monoclonal antibody used in cancer treatment. It has a high affinity for EGFR frequently associated with the growth of blood vessels in ...
T39730	Datopotamab deruxtecan	2238831-60-0	98%
T39730	Datopotamab deruxtecan (DS-1062; Dato-DXd) is a trophoblast cell surface antigen 2 (TROP2)-directed antibody-drug conjugate (ADC) . Datopotamab deruxtecan has a ...
T35385	Isatuximab (anti-CD38)		98%
T35385
T9923	Nimotuzumab	828933-51-3	98%
T9923	Nimotuzumab is a humanized therapeutic monoclonal antibody against epidermal growth factor receptor EGFR).
T38951	Isatuximab	1461640-62-9	98%
T38951	Isatuximab is a monoclonal antibody targeting the transmembrane receptor and ectoenzyme CD38 , a protein highly expressed on hematological malignant cells, inclu...
T35394	Sintilimab (anti-PD-1)		98%
T35394